Fig. 1 · Structure

Documents & Downloads

Methacycline HCl

Cat. No. A10574 CAS 3963-95-9
Methacycline hydrochloride (Physiomycine) is a tetracycline antibiotic.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
protein synthesis

Methacycline HCl Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Methacycline HCl from 3 published references. In vitro models include falcipain-2. In vivo models include female BALB/c mice.

Methacycline HCl In Vitro Studies

Methacycline was evaluated against falcipain-2 using Z-LR↓AMC as the substrate, with DMSO vehicle controls. The reported IC50 was 106.4 μM. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Inhibition of falcipain-2 peptidolytic activity

Cell-based study · falcipain-2 [1]

Methacycline inhibits the peptidolytic activity of falcipain-2, with measurable IC50 and Hill slope values of 106.4 μM and −0.9294. For methacycline, no inhibition was observed in the hemoglobinase activity assay, even at the highest concentration tested (1 mM).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Half-maximal inhibitory concentration (IC50)IC50 106.4 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
375 μM to 44.7 pM
Exposure duration
incubated in darkness for 15 min at 30°C
Method
added to the first wells
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Methacycline

The paper names Methacycline without stating the salt or form; not verified as the hydrochloride form supplied as A10574. No dose conversion or lot validation.

Materials and Methods > Falcipain-2 Kinetic Assay (S112, S114); Materials and Methods > Falcipain-2 Inhibition Assay (S120, S124, S125, S127, S132); Results (S241); Figure 5 legend (S306)

Half-maximal inhibitory concentration (IC50): Half-maximal inhibitory concentration (IC50); comparator: equivalent volumes of DMSO vehicle — Materials and Methods > Falcipain-2 Kinetic Assay (S112, S114); Materials and Methods > Falcipain-2 Inhibition Assay (S132); Results (S241)

Methacycline HCl In Vivo Studies

In female BALB/c mice with intraperitoneal E. coli infection, oral Methacycline monotherapy at 20 mg/kg increased survival from 20.00% in solvent-treated controls to 40.00%. In the liver inflammation study, infected female BALB/c mice received oral Methacycline at 10 mg/kg; neither methacycline nor plumbagin treatment notably reduced inflammation. [2,3]

Survival in an intraperitoneal bacterial infection model

Animal study · Female BALB/c mice, aged 6–8 weeks; intraperitoneal infection model; E. coli 47EC; n = 15 per group [2]

Female BALB/c mice with intraperitoneal E. coli infection received oral Methacycline monotherapy at 20 mg/kg once every 12 h. Survival increased from 20.00% in solvent-treated controls to 40.00% with Methacycline.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
survival ratesurvival rate 40.00%[2]

Conditions shared by the study groups

Route
orally fed
Treatment course
once every 12 h
Vehicle
0.5% CMC-Na
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Methacycline 20 mg/kgsolvent-treated, controlincreased from 20.00% (solvent-treated, control) to 40.00% (20 mg/kg of methacycline-treated, monotherapy)[2]
Methacycline 20 mg/kg
Model: Female BALB/c mice, aged 6–8 weeks; intraperitoneal infection model; E. coli 47EC; n = 15 per group
Methods and source locations

Compound reported in the paper: Methacycline

The paper names Methacycline without stating the salt or form; not verified as the hydrochloride form supplied as A10574. No dose conversion or lot validation.

Materials and methods > Bacterial strains and reagents (S8); Materials and methods > Mouse infection model assays (S57, S59); Results > The combination of mefloquine and methacycline effectively protected mice from intraperitoneal infections caused by E. coli (S139)

survival rate: survival rate; comparator: solvent-treated, control — Results > The combination of mefloquine and methacycline effectively protected mice from intraperitoneal infections caused by E. coli (S139)

Methacycline 20 mg/kg · Materials and methods > Mouse infection model assays (S59); Results > The combination of mefloquine and methacycline effectively protected mice from intraperitoneal infections caused by E. coli (S139)

Liver inflammation in infected mice

Animal study · Female BALB/c mice (6-8 weeks old) [3]

Infected female BALB/c mice received Methacycline orally at 10 mg/kg every 12 h, with infected solvent-treated mice serving as controls. Neither methacycline nor plumbagin treatment notably reduced inflammation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The production of the inflammatory mediators interleukin IL-6 (d), IFN-γ (e) and tumour necrosis factor (TNF)-α (f) in the liverReported result Neither methacycline nor plumbagin treatment notably reduced inflammation.[3]

Conditions shared by the study groups

Route
oral administration
Treatment course
every 12 h
Vehicle
control solvent
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Methacycline 10 mg/kgThe infected mice treated with control solvent served as controls.Neither methacycline nor plumbagin treatment notably reduced inflammation.[3]
Methacycline 10 mg/kg
Model: Female BALB/c mice (6-8 weeks old)
Methods and source locations

Compound reported in the paper: Methacycline

The paper names Methacycline without stating the salt or form; not verified as the hydrochloride form supplied as A10574. No dose conversion or lot validation.

Methods > Mice infection assays (S78, S80, S81); Results > Plumbagin in combination with tetracyclines synergistically protected mice from systemic infection (S217, S222, S224)

The production of the inflammatory mediators interleukin IL-6 (d), IFN-γ (e) and tumour necrosis factor (TNF)-α (f) in the liver: The production of the inflammatory mediators interleukin IL-6 (d), IFN-γ (e) and tumour necrosis factor (TNF)-α (f) in the liver; comparator: The infected mice treated with control solvent served as controls. — Results > Plumbagin in combination with tetracyclines synergistically protected mice from systemic infection (S217, S224)

Methacycline 10 mg/kg · Methods > Mice infection assays (S81); Results > Plumbagin in combination with tetracyclines synergistically protected mice from systemic infection (S217)

Specifications

Manufacturer Adooq Bioscience
CAS Number 3963-95-9
Formula C22H22N2O8.HCl
Molecular Weight 478.89
Synonyms Adriamicina; Ciclobiotic; Germiciclin; Londomycin; Metacyclin hydrochloride; Metadomus; Methacycline; Physiomycine
SMILES
CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C(=CC=C4)O)C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 3 mg/mL (6.26 mM)
Water 4 mg/mL (8.35 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Methacycline HCl Research References

  1. [1] Alberca LN, Chuguransky SR, Álvarez CL, et al. In silico Guided Drug Repurposing: Discovery of New Competitive and Non-competitive Inhibitors of Falcipain-2. Front Chem (2019). PMID: 31448257 DOI: 10.3389/fchem.2019.00534 Source material
  2. [2] Zhou Q, Xue J, Li J, et al. Innovative application of mefloquine and Methacycline in combating Tet(X3/X4)-positive Escherichia coli infections. BMC Microbiol (2025). PMID: 41462086 DOI: 10.1186/s12866-025-04516-0 Source material
  3. [3] Xu L, Zhou Y, Niu S, et al. A novel inhibitor of monooxygenase reversed the activity of tetracyclines against tet(X3)/tet(X4)-positive bacteria. EBioMedicine (2022). PMID: 35306337 DOI: 10.1016/j.ebiom.2022.103943 Source material

Added to your cart

View Cart Checkout
Loading...